The validations confirm the completion of the applications and commence the scientific review process
Uppilliappan joined Dr. Lal Pathlabs in 2016 as Chief Operating Officer and later became CEO
Sharma joined the Morepen Lab in 2004
Acquisition of exclusive commercialization rights for European markets
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
_256_384.jpg)
The Vice President also highlighted the importance of preventive healthcare and fitness
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
Subscribe To Our Newsletter & Stay Updated
